CTOs on the Move

Bio-Path Holdings

www.biopathholdings.com

 
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Bio-Path Holdings raised $13M on 02/16/2021

Similar Companies

Pharma Connections Worldwide

Pharma Connections Worldwide is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Actuate Therapeutics

Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.

MouldWorks

MouldWorks, LLC is a Beulah, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sangart

Sangart is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PepGen

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.